Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03564626 · ClinicalTrials.gov registry record · NA
Health IT Generated PROs to Improve Outcomes in Cirrhosis
A NA study, sponsored by Virginia Commonwealth University.
- Completed
- Registry status
- NA
- Development phase
- 232
- Enrollment target
NCT03564626: Completed NA study, sponsored by Virginia Commonwealth University.
NCT03564626 is a NA study that has completed, run by Virginia Commonwealth University. The registered enrollment target is 232 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (83% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03564626, a NA study, has completed, sponsored by Virginia Commonwealth University.
- COMPLETED
- Registry status
- NA
- Development phase
- 232 participants
- Enrollment target
Study Summary
SPECIFIC AIM 1: To evaluate in a multi-center, randomized trial the effectiveness of PROs elicited using PatientBuddy and EncephalApp on the prevention of avoidable 30 day readmissions in patients with cirrhosis and their caregivers compared to standard of care.
Primary Outcome
Avoidable readmissions within 30 days
Interventions
- OTHER Health-IT +/- Scheduled Follow Up
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 232 participants |
| Start Date | 2018-06-22 |
| Est. Completion | 2024-05-22 |
| Phase | NA |
What the finished NCT03564626 record still lists
NCT03564626 is an interventional study that assigns participants to a tested intervention. The registered 232 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (83% lower).
The record links to 0 conditions, and to 1 intervention - of which Health-IT +/- Scheduled Follow Up is the first listed.
NCT03564626 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03564626 about?
NCT03564626 is a clinical study titled "Health IT Generated PROs to Improve Outcomes in Cirrhosis". SPECIFIC AIM 1: To evaluate in a multi-center, randomized trial the effectiveness of PROs elicited using PatientBuddy and EncephalApp on the prevention of avoidable 30 day readmissions in patients with cirrhosis and their caregivers compared to standard of care.
What is the current status of trial NCT03564626?
This trial is currently completed. It is a NA study. The enrollment target is 232 participants. The study started on 2018-06-22. Estimated completion is 2024-05-22.
What interventions are being tested in trial NCT03564626?
The interventions under investigation include: Health-IT +/- Scheduled Follow Up (OTHER).
Who is sponsoring clinical trial NCT03564626?
This trial is sponsored by Virginia Commonwealth University, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03564626's enrollment target sits among peer trials
232 463rd of 2000 higher than 1,536 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01356290 · 232 participants · Phase 2
Antiangiogenic Therapy for Children With Recurrent Medulloblastoma, Ependymoma, ATRT and Rare CNS Tumors
- NCT04753359 · 232 participants · NA
Mediterranean Diet and Weight Loss: Targeting the Bile Acid/Gut Microbiome Axis to Reduce Colorectal Cancer
- NCT04770870 · 232 participants · NA
Post Approval Study2: Hintermann Series H3 Total Ankle Replacement System
- NCT05948943 · 232 participants · Phase 2
Alpelisib in Pediatric and Adult Patients With Lymphatic Malformations Associated With a PIK3CA Mutation.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI